Although these rare mutations account for a low percentage in the population, they are highly significant for carriers and represent a precise direction for future clinical research.
← all excerpts
Molecular profiling-directed individualized adjuvant therapy in colorectal cancer: Bridging consensus guidelines to clinical disparities.
1
—
—